The Motley Fool

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?

Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech’s next potential product addresses the extremely common problem of pain -- and could become its next ...
The Motley Fool

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication ...
Seeking Alpha

V2X, INC. ANNOUNCES SALE OF 2,000,000 SHARES OF COMMON STOCK IN SECONDARY OFFERING BY VERTEX AEROSPACE

MCLEAN, Va., May 15, 2025 /PRNewswire/ -- V2X, Inc. (VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2 million shares of its common stock on an underwritten ...
Seeking Alpha

V2X, INC. ANNOUNCES SALE OF 2.0 MILLION SHARES OF COMMON STOCK IN SECONDARY OFFERING BY VERTEX AEROSPACE

MCLEAN, Va., Aug. 8, 2025 /PRNewswire/ -- V2X, Inc. (VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.0 million shares of its common stock on an underwritten ...